School of Medicine


Showing 51-92 of 92 Results

  • Ronald Levy, MD

    Ronald Levy, MD

    Robert K. and Helen K. Summy Professor in the School of Medicine

    Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.

  • Michael Lim, M.D.

    Michael Lim, M.D.

    Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology

    BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.

    Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.

    As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.

    Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.

    Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.

    Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.

    Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.

  • Beverly S. Mitchell, M.D.

    Beverly S. Mitchell, M.D.

    George E. Becker Professor of Medicine and Professor, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.

  • Joel Neal, MD, PhD

    Joel Neal, MD, PhD

    Associate Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsI am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.

  • Kim-Son Nguyen

    Kim-Son Nguyen

    Adjunct Clinical Assistant Professor, Medicine - Oncology

    BioDr. Kim-Son H. Nguyen obtained his Bachelor of Arts degree from Harvard College, with a concentration in genetics, his Doctor of Medicine from Harvard Medical School, and Master of Public Administration from the Harvard Kennedy School of Government before becoming a faculty member of Harvard Medical School. He then completed his fellowship in hematology and oncology at Stanford University School of Medicine and Stanford Cancer Institute. While maintaining an active clinical practice at Palo Alto Medical Foundation, Dr. Nguyen is an adjunct clinical assistant professor of medicine at Stanford University School of Medicine, with research interests including the molecular epidemiology of lung cancer, cancer screening, cancer therapeutics, and cancer care delivery.

    With a unique training and extensive experience in cancer genetics, clinical research, and public policy, Dr. Nguyen has been involved in improving cancer care globally for many years. A former director of the American Society of Clinical Oncology International Program in Vietnam, he is passionate about bringing the latest oncology knowledge to cancer-treating health care providers in resource-limited settings, improving cancer care in disadvantaged patient populations, and promoting clinical research in developing countries.

  • Minggui Pan, MD, PhD

    Minggui Pan, MD, PhD

    Clinical Professor, Medicine - Oncology

    BioDr. Pan is a board-certified, fellowship-trained medical oncologist with the Stanford Medicine Cancer Center and a clinical professor in the Department of Medicine, Division of Oncology.

    He diagnoses and treats various oncological conditions and specializes in the treatment of bone and soft tissue sarcoma. He creates personalized and comprehensive care plans for each patient he serves.

    Dr. Pan’s research focuses include understanding how genomic alterations impact the biological behavior and prognosis of sarcomas. In his work, he identifies new targets for developing innovative therapeutics for sarcoma treatment.

    He has published more than fifty papers and many abstracts and presented in many cancer and immunology conferences. His papers have been published in the Journal of Clinical Oncology, JCO Precision Oncology, Clinical Cancer Research, Nature Review Clinical Oncology, JCO Oncology Practice, Journal of Hematology and Oncology, and other peer-reviewed journals. He has also presented to his peers at international, national, and regional meetings, including the annual meetings of American Society of Clinical Oncology, Chinese Society Of Clinical Oncology, Connective Tissue Oncology Society and others.

    Dr. Pan is a member of American Society of Clinical Oncology, American Association of Immunologists, American Association for Advancement of Science, Society for Immunotherapy of Cancer, and Connective Tissue Oncology Society. Dr. Pan is also an adjunct investigator with Kaiser Permanente Division of Research.

  • Divya Parikh, MD

    Divya Parikh, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Divya Parikh is board-certified in both medical oncology and internal medicine. She obtained her medical degree from Boston University School of Medicine and completed both her residency and fellowship through Stanford University. During her fellowship, she simultaneously earned a Master of Science in health policy from Stanford University.

    Dr. Parikh specializes in the care of patients with genitourinary cancers. In addition to her clinical responsibilities, she currently is a clinical assistant professor of medical oncology at Stanford School of Medicine. She mentors medical residents and fellows by sharing her insights, knowledge, and expertise.

    Dr. Parikh has a strong research background. She has published in multiple academic journals and presented her findings through poster and oral presentations at various medical conferences.

  • Mark Pegram

    Mark Pegram

    Susy Yuan-Huey Hung Professor

    Current Research and Scholarly InterestsMolecular mechanisms of targeted therapy resistance in breast and other cancers

  • Harlan Pinto

    Harlan Pinto

    Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery

    Current Research and Scholarly InterestsClinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer

  • Kavitha Ramchandran

    Kavitha Ramchandran

    Clinical Professor, Medicine - Oncology

    Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.

    In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs.

  • Fauzia Riaz, M.D., M.H.S.

    Fauzia Riaz, M.D., M.H.S.

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Riaz is a medical oncologist specializing in breast cancer whose research focuses on novel therapeutics and approaches cancer care delivery for patients with breast cancer. She is currently a Clinical Assistant Professor in the Department of Medicine at Stanford University School of Medicine. Dr. Riaz completed formal research training during her fellowship, through Yale University’s Advanced Health Sciences Research program. This included training in biostatistics, research methodology, and health policy, ultimately culminating in the completion of a Master of Health Sciences. As faculty, she is an active member of the Stanford Breast Oncology Clinical Research Group, and currently serves as the Stanford site principal investigator and sub-investigator for several ongoing breast cancer clinical trials.

  • Rajat Rohatgi

    Rajat Rohatgi

    Professor of Biochemistry and of Medicine (Oncology)

    Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.

  • Mohana Roy, MD

    Mohana Roy, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in hematology and oncology.

    Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience -- from the moment a patient checks in, to how information about their care is conveyed, and how the complex process of getting cancer care can be made a bit more seamless.

    Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs) and their use to help clinical quality efforts- including in the context of a clinical trial with an electronic PRO portal, through distress screening with the Stanford Medicine Cancer Center, and in improving access to such screening and care for patient with limited English proficiency. She is the recipient of both a clinical innovation award through Stanford and an American Society of Clinical Oncology (ASCO) Merit award.

    She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.

    Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford. She was chief fellow for her graduating year during fellowship as well.

  • Anuja Anand Sathe

    Anuja Anand Sathe

    Instructor, Medicine - Oncology

    Current Research and Scholarly InterestsI am interested in understanding the determinants of therapeutic resistance in cancer. I investigate the composition of the tumor microenvironment and adaptive responses to therapy using single-cell and spatial approaches.

  • Lidia Schapira

    Lidia Schapira

    Professor of Medicine (Oncology)

    BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.

  • Joseph Schroers-Martin

    Joseph Schroers-Martin

    Assistant Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMedical heme/onc focused on molecular cancer diagnostics and novel biomarkers.

  • Sumit Shah

    Sumit Shah

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.

  • Shagufta Shaheen

    Shagufta Shaheen

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.

  • Anjali Sibley MD, MPH

    Anjali Sibley MD, MPH

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Sibley is a Clinical Associate Professor of Medicine (Oncology) at Stanford School of Medicine. She is the Director of the Stanford Medicine Cancer Center in Emeryville and is a board-certified, fellowship-trained hematologist and medical oncologist.

    Her clinical interests include treating solid tumor cancers, lung cancers, blood cancers and benign blood conditions. She is interested in cancer prevention and reducing disparities in hematologic/oncologic care among underserved populations, and successful cancer survivorship programs.

    In addition to responsibilities related to patient care and overseeing the Cancer Center in Emeryville, Dr. Sibley has developed and is leading an innovative cancer survivorship clinic, including an exercise initiative. She also is passionate about advancing clinical trial enrollment for medically underserved populations and she serves on the Cancer Network’s East Bay Health Equity Committee leading lung cancer screening efforts in the East Bay. She is also working on a Stanford Cancer Institute-funded study examining psychosocial factors and cardiac health in Black cancer patients in the East Bay.

    She believes that providing patient care is a true privilege. Dr. Sibley utilizes a patient-centered practice approach that addresses multiple aspects of a patient’s well-being. Her research interests have included chemoprevention of breast cancer and the development of magnetic resonance imaging technology in breast cancer detection and mapping. She has also led community-based efforts to implement low-dose computed tomography (LDCT) as a screening tool for cancer.

    Dr. Sibley’s publications include articles on breast cancer prevention, breast magnetic resonance imaging, and other topics. Her work has appeared in American Journal of Hematology, JAMA, the Breast Journal, Internal Medicine News, and elsewhere. Dr. Sibley was invited to deliver a peer-reviewed presentation on community-based cancer screening and preventive education to the Global Health Council. Dr. Sibley is on the board of directors of the Cancer Support Community SF Bay Area. She has also served as a clinic physician for the Native American Health Center of Oakland, on the Committee on Health Equity of the American Public Health Association, and as chair and vice chair of the Cancer Forum Caucus of the American Public Health Association. She is a member of the American Society of Clinical Oncology, American Society of Preventive Oncology, and American Society of Hematology. She has provided volunteer services to the Global Health Council and to the Cancer Patients Aid Association, for whom she conducted a patient screening and education program in Mumbai, India.

  • Branimir I. Sikic, M. D.

    Branimir I. Sikic, M. D.

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers

  • Allyson Spence

    Allyson Spence

    Clinical Assistant Professor, Medicine - Oncology

    BioAllyson Spence MD, PhD is a Clinical Assistant Professor of Medicine in the Stanford University School of Medicine. She received her MD, PhD in the MSTP program at Vanderbilt University School of Medicine, studying basic mechanisms of transcription using Saccharomyces cerevisiae as a model system in the laboratory of Dr. Tony Weil. She went on to an internship and residency at the University of Pennsylvania before returning to Stanford to complete her Oncology fellowship training. She did a postdoctoral fellowship at Stanford in the department of Molecular Biology under the auspices of Dr. Margaret Fuller, where she was the recipient of a career award.

    She has transitioned from basic science research to clinical medicine where she sees patients diagnosed with breast cancer. Additionally, she has an appointment at the Palo Alto VA as a staff oncologist where she focuses on women's cancers and women at high risk of developing breast and gynecologic cancers. She is involved in several translational research projects at the VA, as well as being involved in clinical trials.

  • Sandy Srinivas

    Sandy Srinivas

    Professor of Medicine (Oncology) and, by courtesy, of Urology

    Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma

  • Frank E. Stockdale

    Frank E. Stockdale

    Maureen Lyles D'Ambrogio Professor in the School of Medicine, Emeritus

    Current Research and Scholarly InterestsLaboratory and clinical research in breast cancer ; Normal and abornal differentiation and growth

  • Melinda L. Telli, M.D.

    Melinda L. Telli, M.D.

    Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.

  • Haluk Tezcan, MD

    Haluk Tezcan, MD

    Adjunct Clinical Associate Professor, Medicine - Oncology

    BioClinical focus:
    Breast Oncology
    Molecular Diagnostics

    Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.

    He is leading the development of Lexent Bio's liquid biopsy technology, first in response monitoring, overseeing scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director both in academia and private practice, he has firsthand understanding of unmet clinical needs of physicians and patients, and broad experience in clinical trial design and implementation.
    He established the CA.RE.foundation, a cancer research foundation dedicated to enabling clinical trial execution across community oncology sites throughout the Northwest US. He’s independently built multiple software tools to help oncologists in the practical realities of their daily work.

    Before Lexent Bio, he has served as Director of Translational Medicine at Genomic Health and as Vice President leading oncology development at Counsyl, integrating science with clinical product development. He is a steering committee member of the ASCO QOPI, a quality care initiative.

  • Heather Wakelee

    Heather Wakelee

    Winston Chen and Phyllis Huang Professor

    Current Research and Scholarly InterestsDr. Wakelee's research is focused on clinical trials and translational efforts in patients with lung cancer and other thoracic malignancies such as thymoma and thymic carcinoma. Other interests include translation projects in thoracic malignancies and collaborations with population scientists regarding lung cancer questions.